Sales of Amylin Pharmaceuticals'
Metric |
March 2007 |
June 2007 |
Sept. 2007 |
Dec. 2007 |
March 2008 |
June 2008 |
---|---|---|---|---|---|---|
Byetta sales (in millions) |
$146.5 |
$152.1 |
$161.1 |
$176.3 |
$158.5 |
$177.5 |
Year-over-year growth |
114% |
54% |
27% |
29% |
8% |
17% |
Amylin's other drug, diabetes treatment Symlin, saw a 50% increase in sales over the year-ago quarter, but since it's just 11% of total revenue, its growth didn't help overall revenue too much.
Amylin is trying to keep the momentum going, increasing its sales force by 40% through a reworking of its marketing partnership with Eli Lilly
Byetta's short-term performance probably isn't all that important, since Amylin's turn toward profitability depends on its once-weekly version of Byetta, developed using Alkermes'
In the meantime, Amylin continues to run clinical trials in hopes of amassing as much data as possible to support the sales of the drug once it's approved. It's testing once-weekly Byetta against Merck's
The good news? Even if it has to wait until June of next year to submit, Amylin won't run out of money anytime soon. It still has more than $890 million in cash and short-term investments to tide it over.
More high-growth hoopla: